FDA panel unanimously supports new RSV antibody drug for infants

(NaturalNews)

(Natural News) A panel of independent advisors to the Food and Drug Administration (FDA) has thrown its support behind a new preventive antibody treatment for respiratory syncytial virus (RSV) in newborns and infants.All 21 members of the FDA's Antimicrobial Drugs Advisory Committee (AMDAC) unanimously voted in favor of the monoclonal … [Read More...]